北京大学学报(医学版) ›› 2014, Vol. 46 ›› Issue (4): 519-523.

• 论著 • 上一篇    下一篇

伴有膀胱过度活动症症状的良性前列腺增生患者尿液中脑源性神经营养因子的表达

胡浩,许克新△,张晓鹏,方志伟,陈京文,霍飞,王栋,王晓峰   

  1. (北京大学人民医院泌尿外科,北京100044)
  • 出版日期:2014-08-18 发布日期:2014-08-18

Expression of brainderived neurotrophic factor in urine of patients with benign prostatic hyperplasia  complicated overactive bladder symptoms

HU Hao, XU Ke-xin△, ZHANG Xiao-peng, FANG Zhi-wei, CHEN Jing-wen, HUO Fei, WANG Dong, WANG Xiao-feng   

  1. (Department of Urology, Peking University People’s Hospital, Beijing 100044, China)
  • Online:2014-08-18 Published:2014-08-18

摘要: 目的:探讨伴有膀胱过度活动症(overactive bladder,OAB)症状的良性前列腺增生患者尿液中脑源性神经营养因子(brainderived neurotrophic factor,BDNF)的表达水平,以及其与OAB症状严重程度的相关性。方法:根据纳入标准和排除标准共纳入178例拟行经尿道前列腺电切术的良性前列腺增生患者,行常规术前检查及尿动力学检查,采用国际前列腺症状评分表和OAB症状评分表进行症状评估,采用ELISA方法检测患者尿液BDNF表达水平,结果用尿液标本的肌酐(Cr)值进行标准化BDNF/Cr(mg/mol)。结果:中度和重度下尿路症状患者尿液BDNF/Cr平均值分别为(1.189±0.753) mg/mol和(1.817±1.110) mg/mol (P<0.001)。梗阻Ⅲ~Ⅵ级患者尿液BDNF/Cr平均值分别为(1.382±0.945) mg/mol、(1.435±0.938) mg/mol、(1.640±1.104) mg/mol和(1.653±1.019) mg/mol (P>0.05),BDNF/Cr值与梗阻的严重程度无显著的相关关系(r=0.103,P=0.173)。不伴OAB症状和伴OAB症状患者的尿液BDNF/Cr平均值分别为(0.297±0.183) mg/mol和(1.913±0.843) mg/mol (P<0.001)。轻度、中度和重度OAB症状患者的尿液BDNF/Cr平均值分别为(1.501±0.543) mg/mol、(1.806±0.703) mg/mol和(2.560±0.979) mg/mol (P<0.05),尿液BDNF/Cr值与OAB症状的严重程度呈显著的相关关系(r=0.743,P<0.001)。不伴逼尿肌过度活动症状和伴逼尿肌过度活动症状患者的尿液BDNF/Cr平均值分别为(1.194±1.013) mg/mol和(1.917±0.866) mg/mol (P<0.001)。结论:中度和重度下尿路症状的良性前列腺增生患者尿液中BDNF表达水平与梗阻程度没有明显相关性;与不伴有OAB症状的良性前列腺增生患者相比,伴有OAB症状的患者尿液中BDNF的表达水平会明显升高,且与OAB症状的严重程度相关。

关键词: 脑源性神经营养因子, 前列腺增生, 膀胱, 过度活动性

Abstract: Objective:To investigate the expression of urinary brainderived neurotrophic factor (BDNF) in benign prostatic hyperplasia patients with overactive bladder (OAB) symptoms and its correlation with the severity of OAB symptoms. Methods: According to the inclusion and exclusion criteria, a total of 178 patients with benign prostatic hyperplasia who were to undergo transurethral resection of prostate (TURP) were enrolled in this study. All the patients had accepted basic preoperative evaluations, as well as an assessment of their International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS). The patients who had been scheduled for surgery had to take the urodynamic assessment. Urinary BDNF levels were measured by the enzymelinked immunosorbent assay (ELISA) and the results were further normalized to the concentration of urinary creatinine (BDNF/Cr, mg/mol). Results: The urinary BDNF/Cr levels of the patients with moderate and severe lower urinary tract symptoms were (1.189±0.753) mg/mol and (1.817±1.110) mg/mol (P<0.001). The urinary BDNF/Cr levels of the patients with grades Ⅲ-Ⅵ obstruction were (1.382±0.945) mg/mol, (1.435±0.938) mg/mol, (1.640±1.104) mg/mol, and (1.653±1.019) mg/mol, respectively (P>0.05). There was no correlation between the urinary BDNF/Cr levels and the severity of obstruction (r=0.103, P=0.173). The urinary BDNF/Cr levels in the patients with and without OAB symptoms were (1.913±0.843) mg/mol and (0.297±0.183) mg/mol (P<0.001). The urinary BDNF/Cr levels in the patients with mild, moderate and severe OAB symptoms were (1.501±0.543) mg/mol, (1.806±0.703) mg/mol and (2.560±0.979) mg/mol, respectively (P<0.05). There was a correlation between the urinary BDNF/Cr levels and the severity of OAB symptoms (r=0.743, P<0.001). The urinary BDNF/Cr levels in the patients with urodynamic detrusor overativity were significantly higher than those without detrusor overativity [(1.917±0.866) mg/mol and (1.194±1.013) mg/mol, P<0.001]. Conclusion: There is no correlation between urinary BDNF and severity of obstruction in benign prostatic hyperplasia patients with moderate and severe lower urinary tract symptoms. The urinary BDNF levels in patients with OAB symptoms are elevated compared with patients without OAB symptoms, and are correlated with the severity of OAB symptoms.

Key words: Brain-derived neurotrophic factor, Prostatic hyperplasia, Urinary bladder, overactive

[1] 欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报(医学版), 2024, 56(4): 582-588.
[2] 颜野,李小龙,夏海缀,朱学华,张羽婷,张帆,刘可,刘承,马潞林. 前列腺癌根治术后远期膀胱过度活动症的危险因素[J]. 北京大学学报(医学版), 2024, 56(4): 589-593.
[3] 李晋娜,许丽娜,李敏,宋怡,张静,贾龙斌. 急性脑梗死患者血清BDNF、IL-18、hs-CRP水平与血管性认知障碍的相关性[J]. 北京大学学报(医学版), 2024, 56(4): 708-714.
[4] 刘欢锐,彭祥,李森林,苟欣. 基于HER-2相关基因构建风险模型用于膀胱癌生存预后评估[J]. 北京大学学报(医学版), 2023, 55(5): 793-801.
[5] 辛鹏,张昊,姜振明. 膀胱内灌注电灼联合水扩张法治疗女性间质性膀胱炎[J]. 北京大学学报(医学版), 2023, 55(5): 865-870.
[6] 许素环,王蓓蓓,庞秋颖,钟丽君,丁炎明,黄燕波,车新艳. 等体温膀胱冲洗对经尿道前列腺电切术患者干预效果的meta分析[J]. 北京大学学报(医学版), 2023, 55(4): 676-683.
[7] 李志华,黄燕波,庞秋颖,于书慧,陈宇珂,李德润. 膀胱阴道瘘修补术后患者生存质量和心理状态调查[J]. 北京大学学报(医学版), 2023, 55(1): 190-193.
[8] 王飞,秦彩朋,杜依青,刘士军,李清,徐涛. 中危非肌层浸润性膀胱癌的最佳膀胱镜监测强度[J]. 北京大学学报(医学版), 2022, 54(4): 669-673.
[9] 朱琳,张维宇,许克新. 环磷酰胺诱导SD大鼠膀胱疼痛综合征模型的有效性[J]. 北京大学学报(医学版), 2022, 54(4): 735-740.
[10] 王佳文,刘敬超,孟令峰,张威,刘晓东,张耀光. 间质性膀胱炎/膀胱疼痛综合征患者生活质量及相关因素分析[J]. 北京大学学报(医学版), 2021, 53(4): 653-658.
[11] 王起,张维宇,刘献辉,王明瑞,赖金惠,胡浩,徐涛,许克新. 骶神经调节术治疗膀胱逼尿肌无力的疗效分析[J]. 北京大学学报(医学版), 2021, 53(4): 671-674.
[12] 杨洋,陈宇珂,车新艳,吴士良. 经阴道修补膀胱阴道瘘失败的预后因素:巢式病例对照研究[J]. 北京大学学报(医学版), 2021, 53(4): 675-679.
[13] 王田,洪欣,王晓峰. 等离子针状电极在经尿道近输尿管口膀胱肿瘤切除术中的临床应用(附16例报道)[J]. 北京大学学报(医学版), 2020, 52(4): 632-636.
[14] 董文敏,王明瑞,胡浩,王起,许克新,徐涛. Allium覆膜金属输尿管支架长期留置治疗输尿管-回肠吻合口狭窄的初期临床经验及随访结果[J]. 北京大学学报(医学版), 2020, 52(4): 637-641.
[15] 王皓,姜树坤,彭冉,黄毅,王明清,王俊杰,刘承,张帆,马潞林. 个体化尿量控制提高泌尿肿瘤放疗期间膀胱稳定性[J]. 北京大学学报(医学版), 2020, 52(4): 688-691.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!